Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors
Anticancer Research · 2025
DOI: 10.21873/anticanres.17504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Thomas S Weiss und 1 weiteren Autor:innen. Beteiligte Einrichtung: Children's University Hospital (KUNO), Regensburg University Hospital, Regensburg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Proprotein Convertase 9. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's University Hospital (KUNO), Regensburg University Hospital, Regensburg, Germany.
- Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany christa.buechler@ukr.de.
Zitieren
APA
Weiss, T. S., & Buechler, C. (2025). Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors. Anticancer Research. https://doi.org/10.21873/anticanres.17504
Vancouver
Weiss TS, Buechler C. Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors. Anticancer Research. 2025. doi:10.21873/anticanres.17504
BibTeX
@article{Weiss2025,
author = {Weiss, Thomas S and Buechler, Christa},
title = {Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17504}
}
EUVIMED